McMasterLogo_New-2017-300x165
Back
Evidence Summary

What is an Evidence Summary?

Key messages from scientific research that's ready to be acted on

Got It, Hide this
  • Rating:

In people with stable coronary artery disease, coronary artery bypass grafting reduces risk of death and heart attack

Windecker S, Stortecky S, Stefanini GG, et al. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ. 2014 Jun 23;348:g3859.

Review question

In people with stable coronary artery disease, does revascularization reduce risk of death or acute myocardial infarction (heart attack) more than medication alone?

Background

Coronary artery disease is a narrowing of the blood vessels (coronary arteries) that supply oxygen and blood to the heart. This can cause shortness of breath, chest pain, heart attacks and death.

Coronary artery disease can be treated with medications, such as statins, aspirin and beta-blockers. Revascularization is a more invasive treatment that can restore blood flow through or around a blocked blood vessel. The 2 primary methods for revascularization are coronary artery bypass surgery (CABG) and percutaneous coronary intervention (PCI or angioplasty).

  • CABG is an open-heart surgery that uses a healthy blood vessel from another part of the body to bypass the blocked artery.
  • Angioplasty is a nonsurgical procedure that inflates a small balloon within a partly blocked artery to open the artery. Often, stents (tiny tubes) are then placed in the artery to keep it open. Some of these stents are coated with medication that is slowly released (“eluted”) to further prevent the artery from closing up.

How the review was done

The researchers did a systematic review based on studies that were published up to June 2013.

They found 100 randomized controlled trials with 93,553 patients (average age 62 years).

All people had stable coronary artery disease—that is, they were not currently having a heart attack or increasing chest pain.

The revascularization treatments studied were CABG and angioplasty without stents, with paclitaxel-eluting stents (Taxus®), with sirolimus-eluting stents (Cypher®), with zotarolimus-eluting stents (Endeavor®), with zotarolimus-eluting stents (Resolute®), and with everolimus-eluting stents (Xience®/Promus®).

Revascularization treatments, which typically include medications as well, were compared with initial treatment with medication alone.

What the researchers found

The trials were generally of high quality.

Compared with medication alone:

  • CABG and angioplasty with everolimus-eluting stents (Xience®/Promus®) reduced the risk of death;
  • CABG reduced the risk of heart attack; and
  • CABG and angioplasty with paclitaxel-eluting stents (Taxus®), sirolimus-eluting stents (Cypher®), zotarolimus-eluting stents (Endeavor®), zotarolimus-eluting stents (Resolute®) and everolimus-eluting stents (Xience®/Promus®) reduced the risk of later revascularization.

Conclusion

In people with stable coronary artery disease, coronary artery bypass grafting reduces risk of death and heart attack; use of everolimus-eluting stents (Xience®/Promus®) reduces risk of death but not heart attack.

Revascularization vs medication alone in people with coronary artery disease*

Type of revascularization

Effects of revascularization

Coronary artery bypass grafting

Reduction in death, heart attack and later revascularization

Angioplasty with everolimus-eluting stent (Xience®/Promus®)

Reduction in death and later revascularization; no reduction in heart attack

Angioplasty with bare-mental stent

No reduction in death or heart attack; reduced risk of later revascularization

Angioplasty with paclitaxel-eluting stent (Taxus®)

No reduction in death or heart attack; reduced risk of later revascularization

Angioplasty with zotarolimus-eluting stent (Resolute®)

No reduction in death or heart attack; reduced risk of later revascularization

Angioplasty with sirolimus-eluting stent (Cypher®)

No reduction in death or heart attack; reduced risk of later revascularization

Angioplasty with zotarolimus-eluting stent (Endeavor®)

No reduction in death or heart attack; reduced risk of later revascularization

Angioplasty without stent

No reduction in death, heart attack or later revascularization

 



Related Topics


Glossary

Beta-blockers
Medications that slow down the heartbeat, decrease the force of the contractions of the heart muscles, and reduce blood vessel contraction in the heart, brain, as well as the rest of the body.
Randomized controlled trials
Studies where people are assigned to one of the treatments purely by chance.
Stents
Small mesh tubes.
Systematic review
A comprehensive evaluation of the available research evidence on a particular topic.
Vascular
The body's network of blood vessels. It includes the arteries, veins, and capillaries that carry blood to and from the heart.

Related Web Resources

  • Coronary artery disease risk screening

    Health Link B.C.
    Men over 40 and women past menopause or over 50 should get screened for coronary artery disease (CAD) every 1 to 3 years. Your risk is higher if you have diabetes, high blood pressure, abdominal obesity, kidney disease, family history of CAD or if you smoke.
  • High cholesterol: Does reducing the amount of fat in your diet help?

    Informed Health Online
    Eat less saturated fats in your diet to help prevent heart disease. Eat less meat, butter, cheese and cream to improve your health long-term.
  • Statins: Should I Take Them to Prevent a Heart Attack or Stroke?

    OHRI
    This patient decision aid helps people considering taking medicines called statins to lower their risk of heart attack and stroke by comparing the benefits, risks, and side effects of both options. It also includes alternative treatment options to taking statins such as trying to lower risk with lifestyle changes.
DISCLAIMER These summaries are provided for informational purposes only. They are not a substitute for advice from your own health care professional. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the McMaster Optimal Aging Portal (info@mcmasteroptimalaging.org).

Register for free access to all Professional content

Register